BioCentury’s analysis of this year’s AACR meeting unearths orthogonal approaches to high-wattage targets KRAS and TIGIT, details on allogeneic and personalized cell therapies, and targeted protein degradation players beyond the usual suspects. In the run-up...

The shifting balance between oncology candidates and patients available for trials, and the rise of complex modalities, is shaping the way MD Anderson builds partnerships and develops new assets. University of Texas MD Anderson Cancer...

Chi-Med, Inmagene partner on immunological indicationsHutchison China MediTech Ltd. (NASDAQ:HCM; LSE:HCM) granted Inmagene Biopharmaceuticals Co. Ltd. exclusive options to four immunological diseases programs for up to $95 million in development milestones, $135 million in commercial...

The pandemic has only deepened the already heavily-weighted oncology focus of many portfolios, and it’s targeted oncology opportunities that are catching the eyes of buysiders in 2021. A combination of...

SomaLogic tops off recent series AProteomics company SomaLogic Inc. added another $81 million to the crossover-heavy series A financing it disclosed in November, bringing the round’s total to $214 million. New investors in the second close...

It’s been a busy year for Genentech’s business development team as the company adds discovery and early clinical development deals. The latest deal — a partnership with Relay on a SHP2 inhibitor ...

Pfizer’s deal with LianBio will provide the Perceptive-backed, cross-border start-up with a commercial infrastructure in China, while giving the pharma a drug hunter and development partner led by veteran China biotech executives Bing Li and Debra...

A $310 million crossover round will enable Chinese in-licensing play LianBio to “cast a wide net” as it looks to build a broad portfolio, Perceptive’s Adam Stone told BioCentury. Perceptive Advisors seeded,...

Mirati’s shares rose to an all-time high on Monday after the company dropped the latest response rate data in the closely-watched KRAS inhibitor race, but it’s still too early to tell how adagrasib (MRTX849) will...

Public investors again showed their appetite for protein degradation companies Friday, as C4’s upsized IPO was the largest and best-received of three new NASDAQ listings.  Shares of C4 Therapeutics Inc. (NASDAQ:CCCC), a preclinical company based...